BiotechTube

MAU868

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

BK Virus Infection

Conditions

BK Virus Infection

Trial Timeline

Aug 5, 2020 → Feb 10, 2022

NCT ID
NCT04294472

About MAU868

MAU868 is a phase 2 stage product being developed by Vera Therapeutics for BK Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04294472. Target conditions include BK Virus Infection.

What happened to similar drugs?

20 of 20 similar drugs in BK Virus Infection were approved

Approved (20) Terminated (4) Active (0)
✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
✅PTV/r/OBV/DSVAbbVieApproved
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04294472Phase 2Completed

Competing Products

20 competing products in BK Virus Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1273ModernaPhase 1
0
mRNA-1345ModernaPhase 3
0
mRNA-1647ModernaPhase 2
0
mRNA-1345ModernaPhase 1
0
mRNA-1345ModernaPhase 2
0
mRNA-1189ModernaPhase 1
0
mRNA-1893ModernaPhase 1
0
mRNA-1345ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1325ModernaPhase 1
0
mRNA-1345ModernaPhase 3
0
mRNA-1345ModernaPhase 3
0
VAL-181388ModernaPhase 1
0
mRNA-1647ModernaPhase 2
0
mRNA-1345ModernaPreclinical
0
mRNA-1647ModernaPhase 2
0
mRNA-1944ModernaPhase 1
0
mRNA-1345ModernaPhase 3
0
mRNA-1189ModernaPhase 2
0